" Practically every big bio-tech success on the US market has been negative FCF and diluted share holdings with riasings and placements at some point. Its the nature of the beast."
So if the nature of 'the beast' is twenty years of failure, then you are right.
I completely understand the rhetoric you are making, bio-techs take some time to develop a suitable product and sell it to a market. However MSB has continued to over-promise and deliver nothing in the two decades it has been listed here on the ASX.
Two decades, or twenty years. At what point does one realise failure when its front of their eyes?
Also, quoting me on "acting to financial information that was essentially available over a month ago."
I don't own the stock or have any short position, so I've got no incentive to keep on eye on its day to day activities. So to say I have a lot to learn about investing because I didn't see the new straight away is a baseless comment.
MSB Price at posting:
$1.86 Sentiment: None Disclosure: Not Held
(20min delay)